Such RNF168 deficiency-induced R-loop accumulation can heighten the sensitivity of cancer cells to G4/R-loop-stabilizing drugs such as PARP inhibitors (PARPi), pyridostatin, and irradiation. This evidence concerns the gene PARP1 and cancer.